- Home
- NTHI
NTHI
NeOnc Technologies Holdings Inc. Common Stock
as 04-21-2025 4:00pm EST
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 225.0M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 59.0K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.69 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.97 - $25.00 | Next Earning Date: | 01-01-0001 |
| Revenue: | $83,000 | Revenue Growth: | -8.25% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest NeOnc Technologies Holdings Inc. Common Stock News
NTHI Breaking Stock News: Dive into NTHI Ticker-Specific Updates for Smart Investing
GlobeNewswire
7 days ago
NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets
MT Newswires
7 days ago
NeOnc Technologies Expects Full Enrollment in Phase 2a Trialfor NEO100-01 by September
GlobeNewswire
8 days ago
NeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas in September
MT Newswires
11 days ago
NeOnc Technologies Appoints Executive Chairman Amir Heshmatpour as President
GlobeNewswire
12 days ago
NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company’s New President
MT Newswires
12 days ago
Sector Update: Health Care Stocks Fall Premarket Wednesday
MT Newswires
13 days ago
NeOnc Technologies Phase 1 Trial Enrollment for NEO212 Brain Cancer Drug Nears Full Enrollment
GlobeNewswire
13 days ago
NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy
Compare NTHI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NTHI NeOnc Technologies Holdings Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.